Invirsa Stock

Invirsa develops a molecule that promotes ocular DNA repair and the innate immune response to infection and injury.

Sign up today and learn more about Invirsa Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Invirsa Stock

Invirsa is developing a unique, broad platform based on a naturally occurring small molecule (INV-102) that has demonstrated enhanced immune response to infection. INV-102 not only reduces viral infection, and potentially bacterial replication, it also reduces inflammation, while enhancing the bodies wound healing response. Invirsa's technology is first being developed in the ophthalmology and pulmonary space. Invirsa’s technology has the potential to be a first line therapy for common infectious diseases, whether it's the 100 million viral pulmonary infections or the 5 million infectious conjunctivitis cases that occur every year in the US alone.

Funding History

July 2016$149K
July 2017$520K
December 2019$1.8M
December 2022$6.0M
June 2023$7.7M


Board Member

Margaret Groh

Sr. Director and Marketing

Frank Scardena

Founder and CEO

Robert Shalwitz

Board Member

Faith Voinovich


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: